ID   BxPC-3 XL-3
AC   CVCL_E4NA
SY   XL-3
RX   PubMed=23661005;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_72317; Carbozantinib (Cometriq).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Gene deletion; HGNC; HGNC:6770; SMAD4; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val487_Pro492delinsAla (c.1460_1474delGTGTAGGTGCTGTCA); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; None_reported; -; Zygosity=- (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pancreas; UBERON=UBERON_0001264.
DI   NCIt; C9120; Pancreatic ductal adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_E4N9 ! BxPC-3 XL-2
SX   Female
AG   61Y
CA   Cancer cell line
DT   Created: 19-12-24; Last updated: 19-12-24; Version: 1
//
RX   PubMed=23661005; DOI=10.1038/cddis.2013.158; PMCID=PMC3674365;
RA   Hage C., Rausch V., Giese N.A., Giese T., Schonsiegel F., Labsch S.,
RA   Nwaeburu C.C., Mattern J., Gladkich J., Herr I.;
RT   "The novel c-Met inhibitor cabozantinib overcomes gemcitabine
RT   resistance and stem cell signaling in pancreatic cancer.";
RL   Cell Death Dis. 4:e627.1-e627.10(2013).
//